128
U N I T 1
Cell and Tissue Function
30. Roizen NJ, Patterson D. Down syndrome.
Lancet.
2003;361:
1281–1289.
31. Weijerman ME, de Winter JP. The care of children with Down
syndrome.
Eur J Pediatr.
2010;169:1445–1452.
32. Wiseman FK, Afford KA, Tylbulewica VLJ, et al. Down
syndrome—recent progress and future prospects.
Hum Mol
Genet.
2009;18:E75–E83.
33. Rappaport VJ. Prenatal diagnosis and genetic screening—
integration into prenatal care.
Obstet Gynecol Clin North Am.
2008;35:435–458.
34. Sybert VP, McCauley E. Turner’s syndrome.
N Engl J Med.
2004;351:1227–1238.
35. Morgan T. Turner syndrome: diagnosis and management.
Am
Fam Physician.
2007;76:405–410.
36. Gravholt CH. Epidemiological, endocrine and metabolic features
in Turner syndrome.
Eur J Endocrinol.
2004;151:657–687.
37. Elsheikh M, Dunger DB, Conway GS, et al. Turner syndrome in
adulthood.
Endocr Rev.
2002;21:120–140.
38. Frías JL, Davenport ML, American Academy of Pediatrics
Committee on Genetics, Section on Endocrinology. Health
supervision of children with Turner syndrome.
Pediatrics.
2005;111:692–702.
39. Chacko E, Regelmann MO, Costin G. Updates on Turner
and Noonan syndromes.
Endocrinol Metab Clin North Am.
2012;41:713–734.
40. Gonxalez L, Witchel SF. The patient with Turner syndrome:
puberty and medical management concerns.
Fertil Steril.
2012;98(4):780–786.
41. Davenport ML. Approach to patient with Turner syndrome.
J Clin Endocrinol Metab.
2010;95(4):1487–1495.
42. Pinsker JE. Turner syndrome: updating the paradigm of clinical
care.
J Clin Endocrinol Metab.
2012;97(6):E994–E1003.
43. National Institutes of Health.
Understanding Klinefelter
Syndrome
. 2013. Available at:
klinefelter-syndrome. Accessed October 11, 2013.
44. Lanfranco F, Kamischke A, Zitzmann M, et al. Klinefelter
syndrome.
Lancet.
2004;364:273–283.
45. Wattendorf DJ, Muenke M. Klinefelter syndrome.
Am Fam
Physician.
2005;72(11):2259–2262.
46. Wikström A, Dunkel L. Klinefelter syndrome.
Best Pract Res
Clin Endocrinol Metab.
2011;25(2):239–250.
47. Groth KA, Skakkebaek A, Høst C, et al. Klinefelter syndrome—a
clinical update.
J Clin Endocrinol Metab.
2013;98(1):20–30.
48. Brent RL. Environmental causes of congenital malformations:
the pediatrician’s role in dealing with these complex clinical
problems caused by a multiplicity of environmental and genetic
factors.
Pediatrics.
2004;113:957–968.
49. Steurerwald U, Weibe P, Jorgensen PJ, et al. Maternal seafood
diet, methylmercury exposure, and neonatal neurologic function.
J Pediatr.
2000;136:599–605.
50. Katzung BG, Masters SB, Trevor AJ.
Basic & Clinical
Pharmacology
. 12th ed. New York, NY: McGraw-Hill Medical;
2013:1039–1043.
51. Ross SA, McCaffery PJ, Drager UC, et al. Retinoids in embryonal
development.
Physiol Rev.
2000;80:1021–1055.
52. Bertrand J, Floyd RL, Weber MK, et al.; for the National Task
Force on Fetal Alcohol and Fetal Alcohol Effects.
Fetal Alcohol
Syndromes: Guidelines for Referral and Diagnosis
. Atlanta, GA:
Centers for Disease Control and Prevention; 2004.
53. Sokol RJ, Delaney-Black V, Nordstrom B. Fetal alcohol
syndrome.
JAMA.
2003;290(22):2996–2999.
54. Wattendorf DJ, Muenke M. Fetal alcohol spectrum disorders.
Am Fam Physician.
2005;72(2):279–285.
55. Riley EP, McGee CL. Fetal alcohol spectrum disorders: an
overview with emphasis on changes in brain and behavior.
Exp
Biol Med.
2005;230(6):357–365.
56. Riley EP, Infante MA, Warren KR. Fetal alcohol spectrum
disorders: an overview.
Neuropsychol Rev.
2011;21(3):75–80.
57. Centers for Disease Control and Prevention. Recommendations
for use of folic acid to reduce the number of cases of spina bifida
and other neural tube defects.
MMWR Morb Mortal Wkly Rep.
1992;41:1–8.
58. Bailey LB. New standard for dietary folate intake in pregnant
women.
Am J Clin Nutr.
2000;71(Suppl):1304S–1307S.
59. Jones J, Lopez A, Wilson M. Congenital toxoplasmosis.
Am Fam
Physician.
2003;67:2131–2138.
60. Kirkham C, Harris S, Grzybowski S. Evidence-based prenatal
care: part I. General prenatal care and counseling issues.
Am Fam
Physician.
2005;71(7):1307–1316.
61. Graves JC, Miller KE. Maternal serum triple analyte screening in
pregnancy.
Am Fam Physician.
2002;65(5):915–920.
62. Qin Q-P, Christiansen M, Pettersson K. Point of care time-
resolved immunofluorometric assay of human pregnancy-
associated plasma protein A: use in first-trimester screening for
Down syndrome.
Clin Chem.
2002;48(3):473–483.
63. Lambert-Messerlian GM, Canick JA. Clinical application of
inhibin A measurement: prenatal serum screening for Down
syndrome.
Semin Reprod Med.
2004;22(3):235–242.
64. Ashoor G, Syngelaki A, Poon LCY, et al. Fetal fraction in
maternal plasma cell-free DNA at 11–13 weeks’ gestation:
relation to maternal and fetal characteristics.
Ultrasound Obstet
Gynecol.
2013;41:26–32.
65. Wilson RD. Amniocentesis and chorionic villus sampling.
Curr
Opin Obstet Gynecol.
2000;12:81–86.
Porth Essentials Resources
Explore these additional resources to enhance learning
for this chapter:
•
NCLEX-Style Questions and Other Resources
on
,
•
Study Guide for Essentials of Pathophysiology
•
Adaptive Learning | Powered by PrepU,
prepu
